Bruker (BRKR) Upgraded at BidaskClub

BidaskClub upgraded shares of Bruker (NASDAQ:BRKR) from a hold rating to a buy rating in a research report report published on Friday.

A number of other research firms have also recently commented on BRKR. Needham & Company LLC initiated coverage on shares of Bruker in a research note on Wednesday, January 2nd. They set a strong-buy rating and a $39.00 target price on the stock. ValuEngine cut shares of Bruker from a buy rating to a hold rating in a research note on Thursday, November 15th. Zacks Investment Research upgraded shares of Bruker from a hold rating to a strong-buy rating and set a $38.00 price objective on the stock in a research report on Monday, November 12th. Morgan Stanley cut shares of Bruker from an equal weight rating to an underweight rating and lifted their price objective for the company from $31.00 to $32.00 in a research report on Thursday, September 20th. Finally, UBS Group began coverage on shares of Bruker in a research report on Tuesday, October 9th. They set a sell rating and a $30.00 price objective on the stock. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Bruker presently has an average rating of Hold and an average target price of $35.57.

NASDAQ BRKR opened at $33.37 on Friday. Bruker has a 12 month low of $26.10 and a 12 month high of $36.38. The company has a market cap of $5.06 billion, a price-to-earnings ratio of 27.58, a PEG ratio of 1.79 and a beta of 1.35. The company has a current ratio of 2.24, a quick ratio of 1.32 and a debt-to-equity ratio of 0.27.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, November 1st. The medical research company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.07. Bruker had a net margin of 5.24% and a return on equity of 27.46%. The company had revenue of $466.60 million for the quarter, compared to analysts’ expectations of $451.88 million. During the same quarter last year, the business earned $0.29 EPS. The firm’s revenue was up 7.1% compared to the same quarter last year. As a group, analysts expect that Bruker will post 1.4 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 21st. Stockholders of record on Monday, December 3rd were given a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a dividend yield of 0.48%. The ex-dividend date of this dividend was Friday, November 30th. Bruker’s payout ratio is currently 13.22%.

Several institutional investors have recently added to or reduced their stakes in BRKR. Janus Henderson Group PLC raised its position in shares of Bruker by 4,114.9% during the third quarter. Janus Henderson Group PLC now owns 2,014,706 shares of the medical research company’s stock valued at $67,392,000 after buying an additional 1,966,906 shares during the last quarter. Marshall Wace LLP raised its position in shares of Bruker by 606.5% during the third quarter. Marshall Wace LLP now owns 1,043,570 shares of the medical research company’s stock valued at $34,907,000 after buying an additional 895,860 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Bruker by 28.4% during the third quarter. AQR Capital Management LLC now owns 2,243,794 shares of the medical research company’s stock valued at $75,055,000 after buying an additional 496,259 shares during the last quarter. Panagora Asset Management Inc. raised its position in shares of Bruker by 5,601.5% during the third quarter. Panagora Asset Management Inc. now owns 416,782 shares of the medical research company’s stock valued at $13,941,000 after buying an additional 409,472 shares during the last quarter. Finally, Morgan Stanley grew its holdings in shares of Bruker by 686.7% in the third quarter. Morgan Stanley now owns 411,277 shares of the medical research company’s stock valued at $13,758,000 after purchasing an additional 358,995 shares in the last quarter. Hedge funds and other institutional investors own 64.85% of the company’s stock.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Featured Story: Why are analyst ratings important in trading stocks?

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit